Israeli drugmaker Teva Pharmaceutical Industries (NYSE and TASE: TEVA) reported its fourth-quarter and full-year 2021 financial results on Wednesday.
The company earned $0.77 per diluted share excluding one-time items in the October to December quarter, up 13% from $0.68 a year earlier. Revenue fell 8% to $4.1 billion, meaning that falling sales have been seen in three of the four quarters of 2021.
Teva was grateful that gains in North American sales of Huntington’s disease treatment Austedo (deutetrabenazine) and migraine product Ajovy (fremanezumab) helped to offset declines in generics, a market that continues to be challenging for many companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze